Asset
TIRASEMTIV
CYTOKINETICS INCORPORATED COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02936635 | phase3 | completed | 2016-10-17 | 2018-10-26 | Cytokinetics | A Study for Patients Who Completed VITALITY-ALS (CY 4031) |
| NCT01378676 | phase2 | completed | 2011-06-01 | 2012-03-01 | Cytokinetics | A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| NCT01486849 | phase2 | completed | 2011-11-01 | 2012-03-01 | Cytokinetics | Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| NCT01709149 | phase2 | completed | 2012-10-01 | 2014-03-01 | Cytokinetics | Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) |
| NCT02496767 | phase3 | completed | 2015-09-03 | 2017-03-09 | Cytokinetics | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year |
FDA applications (0)
This company has no applications containing this asset.